Medical network, June 9, according to the financial times reported that Pfizer's viagra fist products in this year's average price increases more than 20%, completely broke the pricing rules of the industry, and for viagra increases, the U.S. government has not take any measures to this problem. 

 

Viagra has long been a legend in the medical profession, with us sales of $11.48 billion in 2016. 

 

Today, viagra may be in danger of walking down the altar. In theory, viagra's patent protection could be in October 2019, and Pfizer was granted a patent extension to be extended to April 2020. But in 2013, as a result of patent disputes, Pfizer and teva signed an agreement, teva in December 2017, after can sell generic viagra, in 2015, mylan and Pfizer signed a similar agreement. 

 

That means there will be more big players in the ED market, and it will be hard to judge whether viagra will survive. In addition to teva, mylan, other companies (Apotex, Torrent, Amneal and Aurobindo) have also developed generic drugs. 

 

Analysts predict that wanai's sales will fall to $359 million in 2018, with sales of $188 million in 2022. There is no doubt that Pfizer may have a "viagra crisis" this time. 

 

It is reported, in June this year, Pfizer to viagra made a jump of 27.5% of the price adjustment, at the same time, Pfizer has improved its pharmaceuticals market selling drugs in New York have price. 

 

This is not the first time that Pfizer has raised such a high price tag, despite a rigorous review of drug prices. At the start of last year, Pfizer raised the average price of its products by more than 10.6 per cent, just as the industry was on the rise. 

 

Previously, Pfizer has once said, innovative drug is the most valuable and the most important part of the medical cost, to deal with rising health care costs and the cost control and its important role. 

 

Drug prices triggered further concern, people can not help but think of the 2015 Turing company overnight shamelessly toxoplasma infection treatment dara wood prices 55 times, Turing company also overnight into a "shameless of company". 

 

In order to avoid this situation happen again, many large pharmaceutical companies, including Takeda, AbbVie, Allergan, Novo Nordisk and Sanofi company, has promised to limit its products in the price of storm. Other companies, such as Merck and Johnson & Johnson, have also reported "transparency reports", which indirectly explain their control over price rises. 

 

However, Pfizer is not in any of these groups. 

 

The industry is clearly not buying Pfizer's account, and Regeneron pharmaceutical CEO Len Schleifer has criticized the pharmaceutical market for covering up innovation gaps with higher prices. And in the face of criticism from price increases, Pfizer CEO LAN Read response, different companies have different pricing model, the drug in medical use proportion has changed in recent years, it's time to recover the innovative drug research and development costs. 

 

To look at the sales of ED products in recent years. 

 

 

Source: CPM database, China medical industry information center 

 

 

Source: China medical industry information center PDB database 

 

At home and abroad, in general, the demand for sildenafil generally increasing year by year, in the domestic, sildenafil in addition to the original company Pfizer, at present, guangzhou baiyun mountain love posen, jiangsu yabang pharmaceutical two generics approved, up to 28 in the research enterprise. Among them, the broad medicine baiyun mountain as viagra first manufacturer, since 2014 sales growth is rapid, sales income over 400 million yuan in 2016 from a year earlier, the sales increased by 62%. 

 

It remains to be seen whether the rise in the foreign viagra will have an impact on the domestic market.